A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus
TH9507, a stabilized analogue of growth hormone-releasing factor, is being evaluated for its potential to improve insulin sensitivity in patients with type 2 diabetes. The market for diabetes treatments is substantial, with increasing prevalence driving demand for innovative therapies. Given the competitive landscape, which includes established therapies and emerging agents, successful outcomes from this trial could position Theratechnologies favorably. However, the company must navigate potential regulatory hurdles and market access challenges, particularly in demonstrating clear clinical benefits over existing treatments. Diligence should focus on the safety profile and efficacy data to assess market viability.
Indication: Type 2 Diabetes
Modality: small molecule
Target: Growth hormone-releasing factor (GRF) analogue
Sponsor: Theratechnologies
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Growth hormone-releasing factor (GRF) analogue
View original source fields
Condition raw: Type 2 Diabetes
Condition normalized: Type 2 Diabetes
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Growth hormone-releasing factor (GRF) analogue
Target normalized: Growth hormone-releasing factor (GRF) analogue